Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB31F in Malaria-exposed Malian Adults and Children
NCT06413108Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TB31F in malaria (13 arms), sponsored by Radboud University Medical Center. Primary endpoints: Occurrence of at least possibly related solicited local and systemic adverse events at 7 days, Occurrence of at least possibly related unsolicited adverse events at 28 days and 6 more. Started Jul 2024; status: completed.
02
Drugs
TB31F
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06413108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413108.